2- Day vs. 5- Day Terlipressin and Ceftriaxone in the Control Acute Gastroesophageal Variceal Hemorrhage
Launched by E-DA HOSPITAL · Aug 13, 2019
Trial Information
Current as of May 29, 2025
Unknown status
Keywords
ClinConnect Summary
Acute gastro-esophageal variceal hemorrhage is a dreadful complication of portal hypertension. Meta-analysis showed that the combination of vasoconstrictor and endoscopic therapy is superior to endoscopic therapy or vasoconstrictor alone in the control of acute esophageal variceal hemorrhage. Bacterial infections are frequently encountered in cirrhotic patients presenting with acute upper gastrointestinal bleeding. The association of bacterial infections to variceal bleeding may increase the occurrence of variceal rebleeding and mortality. A study has shown that antibiotic prophylaxis in pa...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients were diagnosed to have cirrhosis based on history, physical examinations, image studies or histological examination..
- • 2. Age ranges between 20-80 y/o.
- • 3. Patients presenting with hematemesis and /or melena within 24 hours of inclusion.
- • 4. Esophageal variceal bleeding is controlled by esophageal variceal ligation (EVL). Gastric variceal bleeding is controlled by endoscopic glue ( histoacryl) injection.
- • -
- Exclusion Criteria:
- • 1. Uncertain of bleeding source.
- • 2. Failure in endoscopic therapy.
- • 3. Had variceal bleeding or peptic ulcer bleeding in recent one month
- • 4. has evidence of bacterial infections or possible infection at entry ( such as fever \> 37.5。 C, white blood cells\> 10000/cumm, urine leukocytes \>10/ field, pneumonic patches on chest x-ray, ascitic polymorphonuclear cells \> 250/cumm, cellulitis or other focal infections).
- • 2) ever received antibiotics within 4 weeks before index upper gastrointestinal bleeding.
- • 3) presence of cardiopulmonary embarrassment 4) association with uremia and receiving hemodialysis or peritoneal dialysis. 5) presence of deep jaundice (serum bilirubin \> 10 mg/dl), hepatic encephalopathy stage III or IV, massive or refractory ascites 6) presence of chronic kidney disease ( serum creatinine \> 2 mg/dl) or hepatorenal syndrome 7) Had history of cerebrovascular accident, coronary artery disease, complete AV block or peripheral vascular disorder 6) association with human immunodeficiency virus (HIV) infection, advanced carcinoma or hepatocellular carcinoma Barcelona Club Liver Cancer (BCLC) class C or D.
- • 7) allergy to terlipressin, cephalosporins or penicillin 8) pregnancy. 9) Uncooperative or decline to be enrolled
- • -
About E Da Hospital
E-Da Hospital is a leading medical institution dedicated to advancing healthcare through innovative clinical research and trials. With a commitment to patient safety and ethical standards, the hospital fosters a collaborative environment that integrates cutting-edge technology with comprehensive medical expertise. E-Da Hospital focuses on a wide range of therapeutic areas, aiming to improve treatment outcomes and enhance the quality of life for patients. Through its robust clinical trial program, the hospital actively contributes to the development of new therapies and interventions, ensuring that the latest advancements in medicine are accessible to the community it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kaohsiung, , Taiwan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials